Contineum Therapeutics, Inc. Annual Report Summary (Year Ended December 31, 2025)

Contineum Therapeutics, Inc. (Nasdaq: CTNM) has released its annual report for the fiscal year ended December 31, 2025. This summary distills key insights from their SEC 10-K filing, offering investors a clear look at the company's performance, strategic direction, and financial health. The timely submission of all required reports underscores the company's commitment to sound corporate governance.

Company Profile & Status: Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to finding, developing, and bringing to market new treatments for diseases where current options are limited. The company operates under specific SEC designations: it is a "non-accelerated filer," a "smaller reporting company," and an "emerging growth company." These classifications generally apply to companies with smaller market values and revenues, allowing them to follow simplified reporting rules. This status also indicates that Contineum is likely in an early growth phase, presenting both significant potential and the inherent risks common to early-stage development.

Market Snapshot (as of specific dates):

• Market Value: On June 30, 2025, the market value of Contineum's publicly traded shares (excluding those held by insiders) stood at approximately $102.1 million, with a share price of $3.97.
• Shares Outstanding: As of February 27, 2026, the company had approximately 37.3 million shares of common stock outstanding. Contineum maintains two classes of common stock, Class A and Class B. Investors seeking details on potential differences in voting rights or economic interests between these classes should consult the company's proxy statement (Form DEF 14A).

I. Business Overview

Contineum Therapeutics advances a pipeline of drug candidates designed to target specific biological pathways in neurodegenerative and inflammatory conditions. Their core strategy focuses on:

• Targeted Research & Development (R&D): They concentrate on novel ways drugs work, seeking high therapeutic impact. Their lead candidate, CTNM-001, is in development, and they are also investigating CTNM-002.
• Clinical Development: They rigorously advance their pipeline through clinical trials, aiming for data that supports regulatory submissions.
• Strategic Partnerships: They explore collaborations with larger pharmaceutical companies to speed up development, share costs, and broaden market reach.
• Intellectual Property: They continuously strengthen their patent portfolio to protect their innovative therapies.

III. Risk Factors

Investing in Contineum Therapeutics involves significant risks, typical of the biopharmaceutical industry. These include:

• Clinical Trial Success: Drug candidates like CTNM-001 or CTNM-002 may fail to demonstrate safety or effectiveness in clinical trials, or may not achieve regulatory approval.
• Regulatory Approval: Even with positive clinical data, the FDA or other regulatory bodies may not approve their drug candidates. The regulatory process is lengthy, complex, and uncertain.
• Funding & Dilution: The company currently operates at a net loss and will need substantial additional capital to fund its operations and advance its pipeline. Future financing efforts could significantly dilute existing shareholders.
• Competition: The therapeutic areas Contineum targets are highly competitive, with established pharmaceutical companies and other biotechs developing similar or alternative treatments.
• Intellectual Property Protection: Protecting their intellectual property is crucial. Challenges to patents or the inability to obtain new patents could adversely affect their business.
• Dependence on Key Personnel: The company's success relies heavily on attracting and retaining highly qualified scientific and management personnel.
• Market Acceptance: Even if approved, their products may not gain market acceptance or achieve commercial success.

IV. Management's Discussion and Analysis (MD&A) Highlights

The MD&A section offers management's perspective on Contineum's financial condition and operations. Key highlights for 2025 include:

• Operational Progress: The company advanced its pipeline, with significant research and development investments.
• Clinical Progress:
  • CTNM-001: Contineum successfully completed patient enrollment for its Phase 2 clinical trial in a particular condition in Q3 2025. They anticipate topline data readout in Q2 2026.
  • CTNM-002: The FDA granted Orphan Drug Designation for a particular condition in Q1 2025. Preclinical studies demonstrated positive efficacy signals, supporting an expected Investigational New Drug (IND) application filing in Q4 2026.
• Research & Preclinical: The company advanced several preclinical programs, including identifying a novel target for a rare neurological condition, with initial data supporting further investigation.
• Partnerships: Contineum did not announce or initiate any new major strategic partnerships during 2025.
• Intellectual Property: It secured two new patents covering composition of matter for CTNM-001 and a novel therapeutic method, extending protection through 2040.
• Liquidity and Capital Resources: The company's operations consumed significant cash, necessitating a public offering of common stock to strengthen its finances and extend its cash runway. Management continues to monitor cash burn and evaluate future financing needs.

VI. Future Outlook

For the upcoming year, Contineum Therapeutics plans to:

• Advance Clinical Programs: Successfully complete the Phase 2 trial for CTNM-001 and anticipate topline data readout in Q2 2026.
• Expand Pipeline: File an Investigational New Drug (IND) application for CTNM-002 by Q4 2026, initiating its first human clinical trials.
• Strategic Financing: Actively evaluate financing options to extend its cash runway beyond current projections, potentially through equity offerings, debt, or strategic partnerships.
• Research & Development: Continue investing in preclinical research to identify and develop new drug candidates for future pipeline expansion.

Contineum Therapeutics does not currently pay dividends, a common practice for growth-oriented biopharmaceutical companies that reinvest capital into research and development. Investors should consider the company's long-term growth potential and the inherent risks of a clinical-stage biotech company.

VII. Competitive Position

The biopharmaceutical industry is highly competitive, marked by rapid technological change, intense research and development, and a strong emphasis on intellectual property. Contineum Therapeutics competes with various entities, including:

• Large Pharmaceutical Companies: Established companies with significant financial, technical, and human resources, and extensive experience in drug development, regulation, manufacturing, and commercialization.
• Biotechnology Companies: Other clinical-stage and commercial-stage biotechnology companies developing similar or alternative treatments in the same therapeutic areas.
• Academic and Research Institutions: Universities and public and private research institutions that may develop competing technologies or products.

Key competitive factors include product candidate safety and efficacy, timing of market entry, intellectual property protection, manufacturing capabilities, and marketing and sales resources. In neurodegenerative diseases and inflammatory conditions, specifically, several established companies and emerging biotechs are developing or marketing treatments that could compete with Contineum's pipeline candidates, such as CTNM-001 and CTNM-002. While the company believes its focus on novel mechanisms of action and its intellectual property portfolio offer a competitive advantage, it cannot guarantee sustained differentiation or market success against well-resourced competitors.